Clinical Trial Update: Sequential Bacillus Calmette-Guérin (BCG) and Electromotive Mitomycin-C Versus Bacillus Calmette-Guérin (BCG) Alone for High Risk Superficial Bladder Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial compares sequential Bacillus Calmette-Guérin (BCG) followed by electromotive Mitomycin-C versus BCG alone in high-risk superficial bladder ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (Bacillus Calmette-Guérin)
• Mitomycin-C (electromotive) (Mitomycin-C)

Snippet

Sponsor: University of Rome Tor Vergata | Conditions: Bladder Cancer | Phase 3 | Status: COMPLETED